A detailed history of Alpha Centric Advisors LLC transactions in Valneva Se stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 118,000 shares of VALN stock, worth $522,739. This represents 0.6% of its overall portfolio holdings.

Number of Shares
118,000
Previous 88,252 33.71%
Holding current value
$522,739
Previous $618,000 15.21%
% of portfolio
0.6%
Previous 0.51%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$5.88 - $8.56 $174,918 - $254,642
29,748 Added 33.71%
118,000 $712,000
Q2 2024

Jul 25, 2024

BUY
$7.01 - $9.08 $183,998 - $238,331
26,248 Added 42.33%
88,252 $618,000
Q1 2024

Apr 24, 2024

BUY
$6.64 - $10.76 $183,967 - $298,116
27,706 Added 80.78%
62,004 $491,000
Q4 2023

Feb 14, 2024

BUY
$9.88 - $13.82 $135,435 - $189,444
13,708 Added 66.58%
34,298 $355,000
Q3 2023

Nov 13, 2023

BUY
$11.36 - $15.85 $233,902 - $326,351
20,590 New
20,590 $238,000

Others Institutions Holding VALN

About Valneva SE


  • Ticker VALN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,103,504
  • Market Cap $306M
  • Description
  • Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; ...
More about VALN
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.